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Effective treatment of solid cancers by tumor-directed DC-vaccines still remains a challenge in clinical oncology. For
therapeutic success, knock-down of tumor-specific tolerance appears mandatory before a potent tumor-specific
cytotoxic T-cell response can be triggered by DC-vaccinations. Evidence is emerging that lytic virus infection in tumors
can provide valuable help.
Tumor-responsive cytotoxic T-cells play
an important role in tumorimmunosur-
veillance and have great potential for
curative tumor therapy. When adoptively
transferred, T-cells are able to eradicate
established tumors, and their intrinsic
‘seek and destroy’ function makes them a
unique tool to address metastatic diseases.
Since priming and expansion of cytotoxic
T-cells is governed by dendritic cells (DC),
the development of antitumoral DC-
vaccines has been expedited during the
past decade. However, despite recent pro-
gress, such as Sipuleucel-T (Provenge
TM)
for treatment of metastatic prostate tumors,
DC-based immunotherapies against estab-
lished solid tumors did not meet the high
expectations.
If applied against solid tumors, DC-
vaccines are facing strong tumor-specific
tolerogenic conditions. Tumor-specific
tolerance is the result of complex regula-
tory events and adaptation processes which
allow the tumor to be accepted by the
host’s organism even though a significant
spectrum of immunogenic alterations is
present. The tumor microenvironment
decisively contributes to the development
of tumor-specific tolerance by specifically
recruiting suppressor cell types like tumor-
associated macrophages (TAMs), in par-
ticular those of the M2 phenotype,
regulatory T-cells (Treg) and myeloid
derived suppressor cells (MDSC). These
cells provide an immunosuppressive,
antiapoptotic milieu by release of cyto-
kines such as TGF , IL-10 and IL-6 thus
converting tumor tissue into an immuno-
privileged site. Immunosuppressive func-
tions do not only effectively choke down
priming and expansion of T-cells, but also
promote their functional anergy or may
cause selective deletion. Breaking tumor-
specific tolerance is therefore regarded as
a major goal of cancer immunotherapy.
Tumor-targeted, oncolytic virus infections
could play a pivotal role in this regard.
Many virus species such as adenovirus,
poxvirus, measles, HSV, VSV or Reovirus
have been used as oncolytic agents or were
genetically reengineered for this purpose.
1
Recently, a GM-CSF armed poxvirus
(JX-594) has successfully entered clinical
development.
2 Besides their function to
selectively infect and kill tumor cells,
oncolytic viruses also represent a promising
strategy toinduce tumor-directedimmunity
by induction of local inflammation and
cross-presentation of cellular antigens. It is
now accepted that both oncolysis and
immune response contribute to the thera-
peutic benefit of virotherapy.
3
In a recent study,
4 we investigated
whether a tumor-directed DC-vaccination
in tumor-bearing mice could provoke an
effective antitumoral immune response,
if the tumor is affected by a virus infec-
tion (Fig.1). Injection of the telomerase-
selectively replicating adenovirus hTert-Ad
in subcutaneous tumors led to a fulminant
but transient tumor inflammation charac-
terized by lytic destruction of large tumor
areas and massive lymphocyte infiltrations.
Histologically, tumor inflammation was
apparent at day 3 following virus injec-
tion. Virus clearance was then initiated
and tumor recovery began. According to
our hypothesis, a success of tumor-directed
DC-vaccination, indicated by increasing
numbers of tumor-directed CD8 T-cells,
was only observable when the vaccine was
given during apparent tumor inflamma-
tion. More important, the raised T-cell
response led to a dramatically improved
therapeutic outcome and even facilitated
elimination of prestablished lung colo-
nies, an important requirement for the
treatment of disseminated diseases. Due to
the correlation between oncolytic tumor
inflammation and the success of vaccina-
tion we named this therapeutic regimen
‘oncolysis-assisted DC-vaccination’ (ODC).
Observations that increased T-cell res-
ponses could be successfully raised against
endogenous tumor-associated antigens
such as telomerase and that antitumoral
response increased at the expense of the
virus-directed humoral response corrobo-
rated the physiologic relevance of ODC.
Viral vectors are complex ‘biologics’
and are therefore suspected being trouble-
some in therapeutic applications. We
therefore tried to mimic viral inflam-
mation by use of TLR-ligands that are
currently under clinical investigation as
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vaccination adjuvants. Interestingly, none
of the used TLR ligands could successfully
replace a ‘true’ virus infection in ODC.
Only viral replication and oncolysis
allowed for significant cross-presentation
of tumor-associated antigens by tumor-
resident DCs. Attempts to maximize
ODC-mediated therapeutic efficacy by
depletion of Tregs, a classical intervention
to enhance T-cell-dependent immune res-
ponses, evened out all benefits that were
characteristic for ODC. These findings
are consistent with previous evidence
that Tregs are not only suppressor cells
but actively participate in orchestrating
immune responses.
5 We found that a
compensatory induction of MDSC upon
Treg depletion accounts for the failure
of ODC. Furthermore, it has been
reported that Tregs can undergo a rapid
reprogramming into activated T helper
cells under inflammatory conditions, a
process that might play an important role
in priming T-cell responses against new,
cross-presented antigens.
6 Therefore, it
will be interesting to investigate a putative
role of Treg reprogramming in ODC.
Finally, it will be necessary to confirm the
potential of ODC in the context of other
virus types.
Taken together, our study supports the
growing evidence that viruses are promis-
ing means for cancer immunotherapy.
Correspondingly, it has been demonstrated
that sequential delivery of a tumor-
associated antigen by heterologous carrier
viruses is able to significantly boost anti-
tumoral immunity.
7 Moreover, a large
library of tumor-associated antigens has
been applied via a virus-based platform to
successfully cure tumors thus illustrating the
great potential of viruses as targeted immune
activators.
8 It has been shown that conven-
tional regimen such as radio- or chemother-
apy or targeted molecular therapies are able
to elicit detectable tumor-targeted immune
responses that significantly determine the
therapeutic outcome.
9,10 In the future of
tumor therapy, viruses could be ideally
combined with such conventional or mole-
cular therapies to pursue a multimodal
strategy to break therapy resistance and
boost tumor-directed immunity. In those
complex regimens, intelligent adjustment
of single treatments and their precise
scheduling will be a challengeto fully exploit
the potential of cancer immunotherapy.
Figure1. Schematic comparison of conventional and oncolysis-assisted DC-vaccination. In a conventional DC-vaccination (upper panel), a tumor-
directed DC-vaccine is applied though a solid tumor mass is present in the patient. Consequently, tolerogenic properties of the tumor restrict efficient
T cell priming. For oncolysis-assisted DC-vaccination (lower panel), a lytic virus infection is initiated in the tumor tissue to break tumor integrity and
tolerance, and to provide tumor-associated antigens for cross presentation. Thus, onset of virus-mediated oncolysis and inflammation allows for efficient
DC-vaccination.
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